139 related articles for article (PubMed ID: 30126548)
1. Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase 1/2 Activation.
Koral K; Haynes M; Bowen WC; Orr A; Mars W; Michalopoulos GK
Am J Pathol; 2018 Sep; 188(9):2074-2086. PubMed ID: 30126548
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte-specific protein 1: a novel regulator of hepatocellular proliferation and migration deleted in human hepatocellular carcinoma.
Koral K; Paranjpe S; Bowen WC; Mars W; Luo J; Michalopoulos GK
Hepatology; 2015 Feb; 61(2):537-47. PubMed ID: 25234543
[TBL] [Abstract][Full Text] [Related]
3. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte-Specific Protein-1 Suppresses Xenobiotic-Induced Constitutive Androstane Receptor and Subsequent Yes-Associated Protein-Activated Hepatocyte Proliferation.
Koral K; Bhushan B; Orr A; Stoops J; Bowen WC; Copeland MA; Locker J; Mars WM; Michalopoulos GK
Am J Pathol; 2022 Jun; 192(6):887-903. PubMed ID: 35390317
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Zahavi T; Lanton T; Divon MS; Salmon A; Peretz T; Galun E; Axelrod JH; Sonnenblick A
Oncotarget; 2016 Jan; 7(4):4860-70. PubMed ID: 26695439
[TBL] [Abstract][Full Text] [Related]
7. CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis.
Ge Y; Xiao B; Zhao R; Li B; Yang S; He KF; Gu HJ; Zuo S
Int Immunopharmacol; 2024 Jun; 134():112139. PubMed ID: 38739978
[TBL] [Abstract][Full Text] [Related]
8. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
11. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
12. Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
Wei CT; Chen LC; Hsiang YP; Hung YJ; Chien PH; Pan HL; Chen YJ
Anticancer Res; 2019 Feb; 39(2):695-701. PubMed ID: 30711947
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.
Russell JO; Ko S; Saggi HS; Singh S; Poddar M; Shin D; Monga SP
Am J Pathol; 2018 Jun; 188(6):1389-1405. PubMed ID: 29545201
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
16. Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.
Urabe M; Hikita H; Saito Y; Kudo S; Fukumoto K; Mizutani N; Myojin Y; Doi A; Sato K; Sakane S; Makino Y; Kodama T; Sakamori R; Tatsumi T; Takehara T
Hepatol Commun; 2022 Feb; 6(2):411-422. PubMed ID: 34585534
[TBL] [Abstract][Full Text] [Related]
17. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
[TBL] [Abstract][Full Text] [Related]
18. Effect of sorafenib on murine liver regeneration.
Hora C; Romanque P; Dufour JF
Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
[TBL] [Abstract][Full Text] [Related]
19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
